Clinical trials are the gold standard to determine if our innovative therapies are safe and effective for all patients. At NovaBridge, teams of physicians, scientists and researchers work closely with global investigators to carefully conduct and monitor clinical studies.
Advancing Clinical Research
At NovaBridge we are keenly focused on developing treatments for gastric cancers.
Company Sponsored Trials
To make progress against cancer possible, we are currently conducting clinical studies globally to test the safety and efficacy of our potential new medicines.
Biomarker Research
Providing the right medicine to the right patient is central to NovaBridge’s innovation. Throughout our clinical studies, we create and test approaches to select patients most likely to benefit, to support dose selection, and to enable informed decisions on advancing our therapies to the next phase of testing.
Investigator Sponsored Trials
Consistent with our commitment to scientific innovation and improving patient’s lives, we may provide support for independent investigators to expand scientific knowledge of our treatments by leading their own research projects using our therapies.
Selected Ongoing Clinical Trials
Givastomig
- Phase 2
- CLDN18.2 Positive Metastatic Gastric Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
VIS-101
- Phase 1
- Neovascular Age-Related Macular Degeneration
A Study of VIS-101 (ASKG712) in Patients With Neovascular Age-Related Macular Degeneration
Putting Patients First
Each and every person in our trials plays a powerful role. We are grateful to the patients and families who have participated in our previous and ongoing clinical studies. We work diligently to protect their privacy, dignity, safety and well-being at all times.